Lumito's public new share issue oversubscribed
Lumito AB’s recently completed public new share issue resulted in the subscription of units (share plus warrant) for a total value of approximately MSEK 20.4 before transaction costs. This corresponds to a subscription rate of 102 percent of the offering.
- We are very happy with the outcome, says Lumito’s CEO, Stefan Nilsson.
- Considering the market situation, it is amazing that the offering was fully subscribed; we can now welcome about 600 new shareholders to the company, who invested in it alongside the executive management, the main owners and financial advisors. We will now be able to devote the next 12 months to work in accordance with the plans drawn up in our memorandum, and to proceed with the planned listing on Nasdaq First North together with our advisors.
For more information, please contact:
Lumito AB (publ), CEO Stefan Nilsson, telephone +46767 78 59 05, email@example.com
Lumito is a Swedish company that was founded as a spin-off from a research group at the Division of Atomic Physics and Lund Laser Centre, at Lund University. The company specializes in medical technology for digital pathology. The technology is based on fluorescence from upconversion nanoparticles, and aims to speed up and enhance the quality of tissue sample analysis. By developing a new, innovative analysis instrument with associated reagents, Lumito wants to equip healthcare providers with a powerful tool to meet the personalized healthcare’s requirements of fast and safe diagnostics.